Cribstone Capital Management LLC Sells 2,350 Shares of IDEXX Laboratories, Inc. (IDXX)

Cribstone Capital Management LLC reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,774 shares of the company’s stock after selling 2,350 shares during the period. IDEXX Laboratories comprises about 1.4% of Cribstone Capital Management LLC’s investment portfolio, making the stock its 20th largest holding. Cribstone Capital Management LLC’s holdings in IDEXX Laboratories were worth $2,633,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Pearl River Capital LLC bought a new position in IDEXX Laboratories during the 4th quarter worth $28,000. Sontag Advisory LLC bought a new position in IDEXX Laboratories during the 4th quarter worth $79,000. Quantamental Technologies LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter worth about $92,000. Ipswich Investment Management Co. Inc. bought a new position in shares of IDEXX Laboratories in the 4th quarter worth about $124,000. Finally, ETF Managers Group LLC raised its position in shares of IDEXX Laboratories by 15.8% in the 4th quarter. ETF Managers Group LLC now owns 682 shares of the company’s stock worth $127,000 after acquiring an additional 93 shares in the last quarter. 88.24% of the stock is owned by institutional investors.

IDEXX Laboratories stock traded down $0.76 during midday trading on Thursday, reaching $223.76. The stock had a trading volume of 440,933 shares, compared to its average volume of 522,723. IDEXX Laboratories, Inc. has a 12 month low of $176.11 and a 12 month high of $256.22. The firm has a market capitalization of $19.32 billion, a price-to-earnings ratio of 52.48 and a beta of 0.97.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Friday, February 1st. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.08. The business had revenue of $549.39 million during the quarter, compared to analyst estimates of $546.04 million. IDEXX Laboratories had a negative return on equity of 1,501.97% and a net margin of 17.03%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.43 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 4.69 earnings per share for the current fiscal year.

In other news, insider Giovani Twigge sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $211.77, for a total value of $317,655.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Jacqueline Studer sold 2,529 shares of the business’s stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $210.57, for a total value of $532,531.53. Following the completion of the transaction, the vice president now owns 6,918 shares in the company, valued at approximately $1,456,723.26. The disclosure for this sale can be found here. Insiders have sold a total of 40,144 shares of company stock valued at $8,378,892 in the last quarter. Company insiders own 2.70% of the company’s stock.

IDXX has been the subject of several research analyst reports. Canaccord Genuity lowered their price objective on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th. BidaskClub raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Finally, Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $246.67.

ILLEGAL ACTIVITY WARNING: This piece was reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2019/04/11/cribstone-capital-management-llc-sells-2350-shares-of-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: What is the 52-week high/low?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.